<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3A3A6DD9-400B-4BC4-BAD7-E0A03F2DB60A"><gtr:id>3A3A6DD9-400B-4BC4-BAD7-E0A03F2DB60A</gtr:id><gtr:firstName>Ignatius Chung</gtr:firstName><gtr:surname>Chua</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701311"><gtr:id>4C1E9373-F160-4415-ADCD-72AEC9BB7715</gtr:id><gtr:title>Improving T cell Functional Avidity through CD8 Co-receptor Modification: A Novel Mechanism to Enhance TCR Gene Therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701311</gtr:grantReference><gtr:abstractText>We are exploring a new approach to fight cancer. This involves re-programming part of the immune system known as T cells to kill cancer cells. 
This strategy involves transfering genes into T cells so that a protein known as TCR is expressed on the surface. The modified T cells target cancer cells and have been shown to eradicate tumour cells and prolong the survival of tumour bearing animals. Based on these results, we are about to start a clinical trial in patients with leukaemia.
TCR require other molecules such as CD8 co-receptor to recognise tumour proteins. Both molecules need to associate closely in order for optimum function. By modifying CD8, we hope to increase the association and therefore the killing potential of the T cells. We will test our CD8 modified T cells in animal models.
Part of this project will also look at how molecules interact on the surface of cells. Trying to visualise these molecules is challenging because they are so small. Advance microscopy techniques will be required to perform the imaging. The information obtained will give further insight on how to improve the function of modified T cells for cancer therapy.</gtr:abstractText><gtr:technicalSummary>It is possible to redirect the antigen-specificity of T cells using retroviral mediated TCR gene transfer. The host laboratory is using this approach to generate tumour antigen-specific T cells for adoptive transfer. Following TCR gene transfer, transduced T cells usually display the same functional avidity as the parental clone from which the TCR was isolated. Tumour reactive CTL are often low avidity.
Optimal recognition of target cells by CTL requires binding of the cognate peptide MHC class I complex by both TCR and the CD8 co-receptor. Some CD8 chain mutations have recently been shown to increase CD8 binding affinity with MHC and enhance CTL effector function. 

This project aims to identify and test whether the co-transfer of mutated CD8 molecules can improve the effector function of genetically modified T cells expressing tumour reactive TCRs of low or moderate avidity.

In this project I will generate murine CD8 chain mutants, affecting both MHC binding sites (L58R, S53L, S54V and L58R/I25A) and glycosylation sites (T120A, T121A and T124A). Using retroviral vectors the mutated CD8 molecules will be introduced into CD8 -deficient splenocytes together with three different TCR constructs. The F5 TCR recognises an influenza A nucleoprotein derived peptide presented by H2-Db. The MDM-hi and MDM-lo TCR recognise the same peptide derived from the tumour-associated antigen MDM2 with high and low avidity, respectively. 

In vitro functional assays including tetramer staining, peptide specific cytokine secretion, cytotoxicity assays and peptide titration will be performed to determine the functional avidity of transduced cells expressing the various CD8 mutants. The use of fluorescent energy resonance transfer (FRET) methods in parallel with functional assays will provide additional information on the physical interaction between the CD8 molecules and the TCR complex. Finally, I will test in vivo whether selected mutant CD8 molecules can enhance tumour protection by TCR gene modified CTL.

The following hypotheses will be tested: 
(1) Mutations that alter the MHC class I binding or the glycosylation of CD8 may improve the avidity of TCR-transduced T cells. 
(2) Mutations that alter the MHC class I binding or the glycosylation of CD8 may enhance the interactions between CD8 and TCR as determined by FRET. 
(3) Selected CD8 mutants will augment the anti-tumour effects of TCR-transduced T cells in vivo.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-29</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>259731</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BSI IUIS travel bursary</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>British Society For Immunology</gtr:fundingOrg><gtr:id>8D8D7EE3-ADF9-4DE7-B2CA-F27593870CDB</gtr:id><gtr:outcomeId>ihbvmBavQBW0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1421703E-6A62-41A3-8DA9-4BC10D457E10</gtr:id><gtr:title>Challenges in T cell receptor gene therapy.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4729bfeb366f412287fa45e3088859f6"><gtr:id>4729bfeb366f412287fa45e3088859f6</gtr:id><gtr:otherNames>Uttenthal BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn><gtr:outcomeId>pm_16487_27_22610778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96D29E4E-9001-49BE-A074-A026823E64CE</gtr:id><gtr:title>CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54f9e3e773c769e589346684ebee8e7e"><gtr:id>54f9e3e773c769e589346684ebee8e7e</gtr:id><gtr:otherNames>Ghorashian S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5675de21e8070</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701311</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>